BioWorld24d
NLRP3 inflammasome inhibitors detailed in Merck Sharp & Dohme patent
Merck Sharp & Dohme LLC has patented new 5,6 saturated bicyclic heterocyles acting as NLRP3 inflammasome inhibitors potentially useful for the treatment of atherosclerosis, metabolic ...
Seeking Alpha1mon
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time
it is known as MSD/Merck Sharp and Dohme. It is one of the largest drug companies in the world and often is ranked in the top 5 for revenue. This large pharmaceutical giant provides healthcare ...
BusinessWorld11d
CTA partially grants MSD’s petition for VAT refund
THE COURT of Tax Appeals (CTA) has ordered the Bureau of Internal Revenue (BIR) to refund P14.59 million to the local branch of United States-based pharmaceutical company Merck Sharp & Dohme (MSD), ...
pharmaphorum6y
Lung cancer drug Keytruda to become routinely available on NHS
Merck, Sharp, and Dohme (MSD)’s Keytruda (pembrolizumab) will be available for those with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC), where tumours have ...
BioWorld1mon
NLRP3 inflammasome inhibitors disclosed in Merck Sharp & Dohme patent
Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...